Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 206.69 INR -11.35% Market Closed
Market Cap: 93.7B INR

MARKSANS's latest stock split occurred on Mar 11, 2008

The company executed a 10-for-1 stock split, meaning that for every share held, investors received 10 new shares.

The adjusted shares began trading on Mar 11, 2008. This was the only stock split in MARKSANS's history.

Last Splits:
Mar 11, 2008
10-for-1
Pre-Split Price
N/A
Post-Split Price
1.42
Before
After
Last Splits:
Mar 11, 2008
10-for-1

Marksans Pharma Ltd
Stock Splits History

MARKSANS Stock Splits Timeline
Mar 11, 2008
Mar 11, 2008
Split 10-for-1
x10
Pre-Split Price
N/A
Post-Split Price
1.42
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 1, 2025
I
Icon Energy Corp
NASDAQ:ICON
1-for-40
/40
0.0478 1.912 USD 1.79 1.79 USD
Apr 1, 2025
V
Vortex Energy Corp
CNSX:VRTX
1-for-10
/10
0.075 0.075 CAD 0.11 0.11 CAD
Apr 1, 2025
R
Resource Centrix Holdings Inc
CNSX:RECE
10-for-1
x10
2.4 0.24 CAD 0.24 0.24 CAD
Apr 1, 2025
V
Vortex Energy Corp
OTC:VTECF
1-for-10
/10
0.05 0.5 USD 0.0378 0.0378 USD
Mar 31, 2025
Utime Ltd
NASDAQ:WTO
1-for-10
/10
0.151 1.51 USD 1.58 1.58 USD
Load More

Marksans Pharma Ltd
Glance View

Economic Moat
Narrow
Market Cap
93.7B INR
Industry
Pharmaceuticals

Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.

MARKSANS Intrinsic Value
196.81 INR
Overvaluation 5%
Intrinsic Value
Price
Back to Top